HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with high unmet medical needs, announced new preclinical data showing that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation. The compound demonstrated a dose-dependent and statistically significant reduction in pro-inflammatory cytokines IL-6, IL-1β, IL-2, KC/Gro, and inflammasome marker NLRP3—key factors in Alzheimer’s disease progression. Notably, the effects were independent of amyloid beta or tau pathology, highlighting INM-901’s broader potential in treating neurodegenerative diseases. The orally administered compound also targets CB1/CB2 receptors and PPARs and has shown improvements in cognition and behavior in long-term animal studies. InMed plans to advance INM-901 through additional preclinical and IND-enabling studies with a lead indication in Alzheimer’s disease.

To view the full press release, visit https://cnw.fm/fejWH

About InMed

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About HempWire

HempWire (“HW”) is a specialized communications platform with a focus on hemp-related news, information, and the latest developments in the hemp sector. HempWire is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, HW brings its clients unparalleled recognition and brand awareness. HW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from HempWire, text “HempWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.HempWire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.HempWire.com/Disclaimer

HempWire
Austin, Texas
www.HempWire.com
512.354.7000 Office
Editor@HempWire.com

HempWire is powered by IBN